Here it is! The Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) have released updated guidelines for treatment of c-diff. And Dificid just rose to the top. While some of you may be saying “Duh! We already knew Dificid is better,” this is important because doctors reference these guidelines when determining treatment. It may also mean more insurance companies cover it as the first line of treatment rather than waiting for people to fail Vancomycin. New guidelines include:
➡️ For patients with an initial C. difficile episode, fidaxomicin [that’s Dificid] is recommended rather than a standard course of vancomycin.
➡️ For patients with recurrent C. difficile episodes, a standard or extended-pulsed regimen of fidaxomicin should be used rather than a standard course of vancomycin.
➡️ For patients with a recurrent C. difficile episode within the past 6 months, bezlotoxumab [that’s Zinplava] and standard-of-care antibiotics should be used rather than standard-of-care antibiotics alone.
Wider than the Sky 